TheraCann Australia Congratulates Ivory Medical (PVT) Ltd., on its Successful Groundbreaking Event

0
25

Sydney, Australia–(Newsfile Corp. – November 17, 2021) – TheraCann Australia Benchmark Pty. Ltd. (TheraCann Australia), a fully owned subsidiary of TheraCann International Benchmark Corp. (TheraCann International), wishes to congratulate Ivory Medical (PVT) Ltd. (Ivory Medical), on its successful groundbreaking event and the commencement of its site preparation.

Ivory Medical has commissioned this unique facility to provide industrial scale, EU GMP compliant, configurable white label medical cannabis products to foreign markets. Under wholesale white label contracts, Ivory Medical will produce, process, and package medical cannabis products to meet client requirements.

This facility is comprised of a purpose-built 54,000 sq. ft. warehouse with a secure indoor vertical rack cultivation area measuring 43,000 sq. ft. on 3 levels measuring 24 ft. tall. The location will also house a secure indoor administration and processing area measuring 11,000 sq. ft. and has been planned and designed to produce up to 163 kilograms of dried cannabis flower (biomass) per year. That biomass will then be extracted into oil to make cannabis oil based products.

TheraCann Australia has been contracted by Ivory Medical, under a 5-year managed services agreement, to provide technical and operational support for this facility. This contract will include the receipt, installation, maintenance, and support of the necessary equipment to produce, process and prepare for the distribution of EU GMP compliant products. The facility is purposely designed as a wholesale, white-label, facility that can ensure the highest quality, repeatable batch medical-grade cannabis products for international research and development, and medical patient applications.

The building materials were fabricated by Allied Steel https://www.alliedbuildings.com/ and purposely planned and designed to be EU GMP compliant. The technologies selected for this project are REP3S compliant, validation they are repeatable, economic, practical, scalable, safe and secure, and are capable of configuring to meet the ever-changing needs of government(s), researcher(s) or medical patient end-user(s).

The cultivation technology selected is Sprout AI’s https://sproutai.solutions/ version 2 automated vertical indoor rolling rack enclosed plant habitat and root chamber technology that can house up to 32 plants per habitat. The first partial order of 140 Sprout AI habitats is in process of final assembly, and preparation for shipment. Up to 1440 Sprout AI units will be utilized to produce Ivory Medical’s high-quality biomass for processing into medical-grade products. Each Sprout AI habitat encompasses an individual control and time cycle which provides Ivory Medical with the maximum flexibility in its selection of crops to be grown. Sprout AI habitats also utilize a staggered harvested schedule of one habitat per hour, and in so doing provide a perpetual harvest of the highest quality, repeatable batch of cannabinoids and terpenes.

The extraction technology selected was United Scientific extraktLAB’s https://extraktlab.com/ integrated equipment solution that will provide for continual processing of raw oil, distillate and isolate cannabis oil for final packaging and preparation for shipment. The first partial order includes but is not limited to E-140 supercritical CO2 extraction, and Terpene Traps are in process of final assembly and shipment. Up to 3 E-140 supercritical CO2 extraction units as well as extraktLAB’s terpene, distillate and isolate separation and formulation equipment will be utilized to produce Ivory Medical’s highest quality and configurable cannabis oil, distillate or isolate for processing.

The packaging technology selected is ATG’s https://www.atgpharma.com/ configurable packaging equipment solution that will provide for continual packaging of configurable formulated cannabis oil into white label products as specified by the client, including but not limited to configurable dosage tincture, gel capsule, vape cartridge and gummy.

The regulatory compliance and record-keeping technology selected is One System One Solution S.A. (OS2’s) https://os2.solutions/ version 7 secure web-based enterprise resource planning and compliance (ERPc) multi-lingual, multi-tax, and multi-country interoperable, configurable EU GMP, ISO 17025, ISO 17001 compliance software which has been approved for use in 9 countries that federally regulate medical cannabis.

According to Shawn Halter, TheraCann International’s Project Manager for Ivory Medical, “We are thankful to be working with the Ivory Medical team, and to have been given the opportunity to provide both the technology and operational management to this project as part of our BenchmarkSOLUTION turn-key solution. Ivory Medical, by utilizing our BenchmarkSOLUTION, will be able to produce, process and distribute, industrial scale, white label, repeatable, configurable, and EU GMP medical cannabis products to the international market.”

For more information on Sprout AI’s press release dated Nov 17, 2021, please visit https://sproutai.solutions/investors/

About TheraCann

TheraCann is dedicated to providing innovative and adaptable solutions to the highly regulated industrial markets such as commercial and medical cannabis, industrial hemp, psychedelic, and vertical urban food production. Their goal is to provide solutions that produce reliable, economic, practical, scalable, safe and secure while setting the gold standard in quality, traceability and regulatory compliance.

For more information about TheraCann, please visit: https://www.theracann.solutions

International Project Manager
Contact: Shawn Halter
TheraCann International
E-mail: shalter@theracann.solutions

Quality Assurance Manager Contact: Ross McPhail
TheraCann Australia
E-mail: rmcphail@theracann.solutions

Website: https://www.theracann.solutions
Address: Level 1, 8 Beulah Road, Norwood SA Australia, 5067

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103951